2016-02-02T13:29:06-06:00 2015-07-31 522041603 SQUIRE LEMKIN COMPANY LLP 111 ROCKVILLE PIKE SUITE 475 ROCKVILLE MD 20850 990 2014-08-01 452410498 RX-360 INTERNATIONAL PHARMACEUTICAL SUPPLY CHAIN CONSORTIUM RX-3 2022305142 1500 K STREET NW NO 1100 WASHINGTON DC 20005 LYNNE BYERS TREASURER 2022305142 2016-02-02 1 NANCY JOHNSON P01593478 3014246800 2014 2016-04-25 22:37:26Z GUY VILLAX 1500 K STREET NW NO 1100 WASHINGTON DC 20005 1712455 0 X WWW.RX-360.ORG X 2009 PA THE MISSION OF RX-360 IS TO PROTECT PATIENT SAFETY BY ENHANCING THE QUALITY OF THE SUPPLY CHAIN AND AUTHENTICITY OF MATERIALS WITHIN THE SUPPLY CHAIN. 25 25 0 0 0 0 0 0 1529248 1683935 0 0 47976 28520 1577224 1712455 0 0 0 0 0 0 0 0 0 1458480 1585951 1458480 1585951 118744 126504 422161 689126 303417 443878 118744 245248 TO CREATE AND MONITOR A GLOBAL QUALITY SYSTEM THAT MEETS THE EXPECTATIONS OF INDUSTRY AND REGULATORS, THAT ASSURES PATIENT SAFETY BY ENHANCING PRODUCT QUALITY AND AUTHENTICITY THROUGHOUT THE PHARMACEUTICAL SUPPLY CHAIN. 0 0 1585951 ENHANCING THE SECURITY OF THE PHARMACEUTICAL SUPPLY CHAIN THROUGH TWO AUDIT PROGRAMS AND RESEARCH PROGRAMS. THE RX-360 AUDIT SHARING PROGRAM ALLOWS RX-360 MEMBERS TO SHARE SUPPLIER QUALITY AUDITS CONDUCTED BY RX-360 MEMBERS OR ON THEIR BEHALF. THE RX-360 JOINT AUDITING PROGRAM ALLOWS RX-360 MEMBERS TO CONDUCT JOINT QUALITY AUDITS OF PHARMACEUTICAL SUPPLIES. RX-360 ALSO ANALYZES NEW LEGISLATION, REGULATIONS, STANDARDS, AND OTHER DEVELOPMENTS THAT IMPACT THE PHARMACEUTICAL SUPPLY CHAIN, AND MAKES THIS INFORMATION AVAILABLE TO RX-360 MEMBERS AND THE PUBLIC VIA RX-360'S WEBSITE. 1585951 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 X 25 25 0 1 0 0 1 1 1 1 1 0 0 1 1 1 0 0 0 0 0 0 X DRINKER BIDDLE & REATH LLP 2022305142 1500 K STREET NW NO 1100 WASHINGTON DC 20005 X BRIAN JOHNSON CHAIR (THROUGH 12/2014), DIRECTOR (8/14-PRESENT)) 3.00 X X 0 0 0 GUY VILLAX DIRECTOR 814 - PRESENT VICE-CHAIR (THROUGH 12/2014), CHAIR (AS OF 1/2015) 3.00 X X 0 0 0 LINDA EVANS O'CONNOR VICE CHAIR (1/15-2/15), DIRECTOR (8/14-PRESENT) 2.00 X X 0 0 0 GWYN MURDOCH DIRECTOR (1/2015 - PRESENT), VICE CHAIR THEREAFTER 3.00 X X 0 0 0 MARTIN VANTRIESTE TREASURER (THROUGH 12/14), DIRECTOR (8/14-PRESENT) 3.00 X X 0 0 0 LYNNE BYERS DIRECTOR (8/14-PRESENT), TREASURER(AS OF 1/2015)1 3.00 X X 0 0 0 MATT ANDERSON DIRECTOR 2.00 X 0 0 0 TOM BEIL DIRECTOR 2.00 X 0 0 0 JANICE BERMAN DIRECTOR 2.00 X 0 0 0 JOSEPH FAMULARE DIRECTOR 2.00 X 0 0 0 HUBERTUS FOLTTMANN DIRECTOR 2.00 X 0 0 0 FRITHJOF HOLTZ DIRECTOR 2.00 X 0 0 0 ALLEN MOSS DIRECTOR 2.00 X 0 0 0 MARK PAVIGLIANITI DIRECTOR 2.00 X 0 0 0 WES SCHMIDT DIRECTOR 2.00 X 0 0 0 MELISSA SEYMOUR DIRECTOR 2.00 X 0 0 0 DAVID WALKER DIRECTOR 2.00 X 0 0 0 GORDON WHITTLE DIRECTOR 2.00 X 0 0 0 CARMEN WOLF DIRECTOR 2.00 X 0 0 0 DANIEL BIRAN DIRECTOR (1/2015 - PRESENT) 2.00 X 0 0 0 MARIE DAWSON DIRECTOR (5/2015 - PRESENT) 2.00 X 0 0 0 DAVID HATT DIRECTOR (2/2015 - PRESENT) 2.00 X 0 0 0 ANISH SWADI DIRECTOR (1/2015 - PRESENT) 2.00 X 0 0 0 KELLY TAYLOR DIRECTOR (6/2015 - PRESENT) 2.00 X 0 0 0 ROB WELSH DIRECTOR (1/2015 - PRESENT) 2.00 X 0 0 0 0 0 0 0 0 0 0 DRINKER BIDDLE & REATH LLP 1500 K STREET NW SUITE 1100 WASHINGTON DC 20005 LEGAL 886510 1 MEMBERSHIP DUES 900099 1017100 1017100 SPONSORED AUDIT FEES 900099 240132 240132 OUTSIDE CONFERENCE REV 900099 180370 180370 LICENSE FEES 900099 160328 160328 DATABASE FEES 900099 86005 86005 1683935 LICENSE AUDIT ADMINIST 900099 26750 26750 SPONSORED AUDIT MANAGE 900099 1770 1770 28520 1712455 1712455 0 0 X 1205720 1205720 5900 5900 232208 232208 15230 15230 126893 126893 1585951 1585951 0 0 395911 651486 26250 37640 422161 689126 50984 51523 252433 392355 303417 443878 X 118744 245248 118744 245248 422161 689126 126504 0 X 0 0 0 0 1 0 0 UNBILLED RECEIVABLE 37640 37640 EUROPE (INCLUDING ICELAND & GREENLAND) - 0 0 PROGRAM SERVICES - AUDITS QUALITY AUDITS OF PHARMACEUTICAL SUPPLIES. 93483 EAST ASIA AND THE PACIFIC - 0 0 PROGRAM SERVICES - AUDITS QUALITY AUDITS OF PHARMACEUTICAL SUPPLIES. 38170 0 0 0 0 0 0 131653 0 131653 0 0 0 0 0 0 PART I, LINE 3: ACCRUAL METHOD IS USED TO ACCOUNT FOR EXPENDITURES. FORM 990, PART VI, SECTION A, LINE 3 DRINKER BIDDLE & REATH LLP (DBR) SERVES AS SECRETARIAT AND LEGAL COUNSEL TO RX-360. DAY TO DAY MANAGEMENT OF RX-360 IS PERFORMED BY DBR. FORM 990, PART VI, SECTION A, LINE 6 ANY LEGAL ENTITY MAY BECOME A MEMBER OF RX-360 IF THE FOLLOWING CRITERIA IS MET: 1. ITS ACTIVITIES RELATE TO THE RESEARCH, DEVELOPMENT, OR MANUFACTURE OF PHARMACEUTICAL OR BIOTECHNOLOGY PRODUCTS, INCLUDING RESEARCH-BASED PHARMACEUTICAL COMPANIES, GENERIC PHARMACEUTICAL COMPANIES, BIOTECHNOLOGY COMPANIES, AS WELL AS SUPPLIERS OF INGREDIENTS AND COMPONENTS OF PHARMACEUTICAL OR BIOTECHNOLOGY PRODUCTS AND SUPPLIERS OF SERVICES RELATING TO THE QUALITY OR SAFETY OF THE PHARMACEUTICAL OR BIOTECHNOLOGY SUPPLY. (PROVIDERS OF AUDITING AND CONSULTING SERVICES ARE NOT ELIGIBLE FOR RX-360 MEMBERSHIP). 2. IT AGREES TO PAY ANNUAL DUES AND ASSESSMENTS THAT ARE SET BY THE BOARD OF DIRECTORS. 3. IF IT IS A GOVERNMENTAL UNIT OR QUASI-GOVERNMENTAL UNIT OR AN EDUCATIONAL INSTITUTION, IT DOES NOT INVOLVE THE LEGISLATIVE, JUDICIAL OR EXECUTIVE BRANCHES OF GOVERNMENT AND ALL STEPS WILL BE TAKEN BY THE ENTITY TO RESIST OR RESTRICT ANY ATTEMPT MADE BY THE LEGISLATIVE, JUDICIAL OR EXECUTIVE BRANCHES TO OBTAIN ACCESS TO RX-360 REPORTS OR CONFIDENTIAL INFORMATION, AND APPROPRIATE MECHANISMS ARE IN PLACE AT THE ENTITY TO ENSURE CONFIDENTIALITY AND TO PREVENT IMPROPER DISCLOSURE. THERE ARE THREE CLASSES OF RX-360 MEMBERS, ONE CLASS FOR MANUFACTURERS OF PHARMACEUTICAL OR BIOTECHNOLOGY FINISHED PRODUCTS WITH $500 MILLION (US DOLLARS) OR MORE IN WORLDWIDE GROSS REVENUE FROM SALES OF PHARMACEUTICAL OR BIOTECHNOLOGY FINISHED PRODUCTS AMOUNG AFFILIATED ENTITIES, ONE CLASS FOR MANUFACTURERS OF PHARMACEUTICAL OR BIOTECHNOLOGY FINISHED PRODUCTS WITH LESS THAN $500 MILLION (US DOLLARS) IN WORLDWIDE GROSS REVENUE FROM SALES OF PHARMACEUTICAL OR BIOTECHNOLOGY FINISHED PRODUCTS AMOUNG AFFILIATED ENTITIES AND CONTRACT MANUFACTURERS OF FINISHED DOSAGE FORM PHARMACEUTICAL AND BIOTCHNOLOGY PRODUCTS AND ONE CLASS FOR SUPPLIERS OF INGREDIENTS AND COMPONENTS OF SUCH PRODUCTS AND SUPPLIERS OF SERVICES RELATING TO THE QUALITY OF SAFETY OF THE PHARMACEUTICAL OR BIOTECHNOLOGY SUPPLY CHAIN. FORM 990, PART VI, SECTION A, LINE 7A ALL MEMBERS HAVE EQUAL VOTING RIGHTS IN ELECTIONS OF OFFICERS. ALL MEMBERS ARE ELIGIBLE TO VOTE IN ELECTIONS OF THE BOARD OF DIRECTORS; HOWEVER, VOTING FOR BOARD MEMBERS IS DONE BY CATEGORY OF MEMBERSHIP. THE BYLAWS STATE THAT APPROXIMATELY 65% OF THE MEMBERSHIP OF THE BOARD SHALL BE COMPRISED OF REPRESENTATIVES OF LARGE FINISHED PRODUCT MANUFACTURERS ; APPROXIMATELY 10%OF THE MEMBERSHIP OF THE BOARD SHALL BE COMPRISED OF REPRESENTATIVES OF SMALL OR CONTRACT FINISHED PRODUCT MANUFACTURERS; AND APPROXIMATELY 25% SHALL BE COMPRISED OF REPRESENTATIVES OF SUPPLIERS. FORM 990, PART VI, SECTION A, LINE 7B THE BYLAWS OF RX-360 STATE THAT THE MEMBERS OF RX-360 HAVE THE POWER TO OVERRIDE ANY AMENDMENTS TO THE BYLAWS ADOPTED BY THE BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 11 THE SECRETARIAT FIRST REVEIWS THE 990. ONCE THE SECRETARIAT IS SATISFIED THAT THE INFORMATION IS ACCURATE AND COMPLETE, IT IS FORWARDED TO THE CHAIR, VICE-CHAIR AND TREASURER FOR THEIR REVIEW. ONCE THEY ARE SATISFIED THAT THE INFORMATION IS ACCURATE AND COMPLETE, THE 990 IS FORWARED TO THE FULL BOARD PRIOR TO SUBMISSION. FORM 990, PART VI, SECTION C, LINE 19 RX-360'S BYLAWS AND ANTI-TRUST POLICY ARE AVAILABLE ON RX-360'S WEBSITE. ALL OTHER FINANCIAL DOCUMENTS THAT ARE REQUIRED TO BE MADE AVAILABLE TO THE PUBLIC WILL BE AVAILABLE THROUGH RX-360'S WEBSITE OR UPON REQUEST. FORM 990, PART IX, LINE 11G AUDIT FEES: PROGRAM SERVICE EXPENSES 232,208. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 232,208.